Holen Sie sich die Stockscreener-App
72.61
0.06%
0.04
Handel nachbörslich:
72.61
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$72.57
Offen:
$72.59
24-Stunden-Volumen:
2.15M
Relative Volume:
0.46
Marktkapitalisierung:
$11.39B
Einnahmen:
$1.21B
Nettoeinkommen (Verlust:
$109.52M
KGV:
104.29
EPS:
0.6962
Netto-Cashflow:
$269.60M
1W Leistung:
+0.33%
1M Leistung:
+0.39%
6M Leistung:
+37.81%
1J Leistung:
+43.84%
1-Tages-Spanne:
$72.56
$72.64
1-Wochen-Bereich:
$72.44
$72.69
52-Wochen-Spanne:
$43.20
$72.69
Bio Techne Corp Stock (TECH) Company Profile
Firmenname
Bio Techne Corp
Sektor
Branche
Telefon
612-379-8854
Adresse
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
72.61 | 11.39B | 1.21B | 109.52M | 269.60M | 0.6962 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-07-22 | Fortgesetzt | Stephens | Overweight |
| 2025-07-09 | Eingeleitet | TD Cowen | Buy |
| 2025-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-09 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-08 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-02-02 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-08-28 | Eingeleitet | William Blair | Outperform |
| 2023-01-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | Hochstufung | Stifel | Hold → Buy |
| 2021-01-25 | Bestätigt | The Benchmark Company | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-07-15 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-14 | Eingeleitet | The Benchmark Company | Buy |
| 2020-01-08 | Fortgesetzt | Stephens | Overweight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-02 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-14 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | Herabstufung | Craig Hallum | Buy → Hold |
| 2018-10-17 | Eingeleitet | Goldman | Neutral |
| 2018-06-15 | Eingeleitet | Argus | Buy |
| 2017-07-13 | Eingeleitet | Wells Fargo | Market Perform |
| 2017-02-09 | Eingeleitet | Citigroup | Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-01-21 | Bestätigt | Robert W. Baird | Outperform |
| 2013-09-20 | Hochstufung | Robert W. Baird | Neutral → Outperform |
Alle ansehen
Bio Techne Corp Aktie (TECH) Neueste Nachrichten
Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package - Insider Monkey
Robert V Baumgartner Exercises Options, Realizes $754K - Benzinga
What Does Bio-Techne Corporation's (TECH) Latest Move Mean for Midcap Stocks Investors? - Kalkine Media
Form 4 Bio-Techne Corp For: 25 September - Investing.com India
Form 4 Bio-Techne Corp For: 25 September By Investing.com - Investing.com South Africa
Bio-Techne (TECH) director exercises options and delivers or withholds 5,559 shares for costs or taxes. - Stock Titan
Bio-Techne shareholders approve $11.3 billion merger with German Merck - AKM.RU
What Does Shareholder Approval Mean for Bio-Techne's (NASDAQ:TECH) Merck KGaA Deal? - Kalkine Media
Is Bio-Techne Stock Outperforming the Nasdaq? - barchart.com
Form 8K Bio-Techne Corp For: 23 September By Investing.com - Investing.com Canada
Form 8K Bio-Techne Corp For: 23 September - Investing.com India
Merck KGaA's USD 11.3b Bio-Techne acquisition clears final shareholder approval hurdle - AllSci
Bio-Techne (TECH) Opens Düsseldorf Hub As Fair Value Questions Come Into Focus - simplywall.st
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany - Investing News Network
Bio-Techne shareholders approve Merck KGaA acquisition - Investing.com
Bio-Techne Shareholders Approve Takeover by Merck KGaA - marketscreener.com
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration - Investing News Network
Bio-Techne Opens New Customer Experience Center in Germany - marketscreener.com
Bio-Techne opens customer experience center in Düsseldorf - Investing.com
Bio-Techne Corp (TECH) Investor Outlook: Navigating Market Dynamics with a Focus on Growth Potential - DirectorsTalk Interviews
Ademi LLP investigates Bio-Techne sale to Merck KGaA - scanx.trade
Bio-Techne Corporation (TECH) Options ChainYahoo Finance - Yahoo! Finance Canada
Bio-Techne issues supplemental merger disclosures amid shareholder lawsuit - Investing.com
Form 8K Bio-Techne Corp For: 14 September By Investing.com - Investing.com Nigeria
Bio-Techne supplements proxy disclosures after shareholder suit, seeks shareholder vote on Sept. 23 - TradingView
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report? - Eastern Progress
TECH: Bio-Techne Corp Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger – AUUD, TECH, CZR and CBAN - GlobeNewswire Inc.
Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others - Yahoo Finance UK
IVD Raw Material Market Report Now Available — Forecasts Market Growth from $21.5B (2026) to $31.1B by 2031, Profiling Merck KGaA, Thermo Fisher, Bio-Techne, Fapon Biotech, and 21 Other Key Players - Yahoo Finance
Bio-Techne Corp (TECH) Stock Analysis: Navigating Its Current Valuation and Growth Potential - DirectorsTalk Interviews
Bio-Techne Corp (NASDAQ: TECH) Share Price, TECH Stock News, TECH Share Price & Updates - Kalkine
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Bio-Techne Corp (TECH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bio-Techne (TECH), What Is Behind The Latest Attention? - simplywall.st
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals - Investing News Network
Legal & General buys $19.51M stake in Bio-Techne - app.dealroom.co
Bio-Techne Corp (TECH) Stock Analysis: Evaluating the Balance Between Growth Potential and Current Valuation - DirectorsTalk Interviews
Bio-Techne Corp (TECH) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Bio-Techne To Be Acquired by Merck KGaA - Morningstar
Bio-Techne draws fresh institutional cash as revenue climbs to $321M - app.dealroom.co
BIO-TECHNE Corp FY 2026: Revenue $1.22B, EPS $1.16— 10-K Summary - TradingView
Bio-Techne Gives FTC More Time On $11.3B Merck Deal - Law360
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation? - TradingView
Bio-Techne (TECH) Momentum: Adds 0.06% to Close at $72.32 in the Current Update; Price Context: the Current Price Sits Inside the Supplied Technical Range on the DayHedge Fund Favorites - careplusvn.com
Bio-Techne (Nasdaq: TECH) investors to vote on Merck cash takeover - Stock Titan
Bio-Techne (TECH) Quarterly Results: EPS Does Not Reach the Reported Estimate in Latest Trading; Price Reaction - careplusvn.com
Bio-Techne (NASDAQ: TECH) GC gets new RSU grants, no stock sales - Stock Titan
Bio-Techne (NASDAQ: TECH) grants CFO 22,438 and 36,459 RSUs - Stock Titan
Bio-Techne (TECH) director granted 1,381 RSUs vesting 2027-29 - Stock Titan
Finanzdaten der Bio Techne Corp-Aktie (TECH)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):